论文信息 - Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM). - 字舞流文

Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM).

K. Flaherty | Douglas B. Johnson | S. Patel | M. Sznol | R. McWilliams | J. Infante | A. Daud | R. Kefford | R. Gonzalez | G. Long | W. Sharfman | L. Schuchter | O. Hamid | J. Weber | J. Cebon | B. Mookerjee | Z. Eroglu | E. Gasal | S. Redhu